Lingwei Dai

Title: Lingwei Dai: Innovator in Soft Gel Formulations

Introduction

Lingwei Dai is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of soft gel capsules. His innovative work focuses on enhancing the stability of specific compounds, which can lead to improved therapeutic applications.

Latest Patents

Lingwei Dai holds a patent for the "Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules." This patent discloses shelf-stable beta-hydroxyisovaleric acid-containing soft gel compositions and methods for making such compositions. The disclosed compositions comprise a plant-based capsule shell and a liquid formulation that includes beta-hydroxyisovaleric acid and at least one excipient. The soft gel capsule is designed to be shelf-stable, ensuring its efficacy over time. The excipients used in these formulations may include choline salt, betaine, phosphatidylcholine, alpha-glycerophosphocholine, carnitine, adenosine 5'-triphosphate, or a combination thereof.

Career Highlights

Lingwei Dai has established himself as a key figure in the pharmaceutical industry through his innovative work. His patent reflects his commitment to advancing drug formulation technologies. He is associated with Tsi Group Co., Ltd., where he continues to contribute to research and development efforts.

Collaborations

Lingwei Dai has collaborated with notable professionals in his field, including Martin Purpura and Ralf Jäger. These collaborations have likely enriched his research and contributed to the success of his innovations.

Conclusion

Lingwei Dai's work in stabilizing beta-hydroxyisovaleric acid formulations represents a significant advancement in pharmaceutical technology. His contributions are poised to enhance the effectiveness of soft gel capsules, benefiting both manufacturers and consumers.